Center for Diab,Obes & Metab

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Type 2 diabetes4 trials
• Obesity3 trials
• Type 1 diabetes1 trial

Phase

• Phase 35 trials
• Phase 11 trial
• Phase 21 trial

Status

• Active, not recruiting3 trials
• Completed2 trials
• Recruiting1 trial
• Withdrawn1 trial

Lead sponsor

• Novo Nordisk A/S7 trials

Running trials

• Recruiting

  Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events

  NCT07607587· Phase 1· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Active, not recruiting

  Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

  NCT07220759· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

  NCT07076199· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

  NCT07011667· Phase 3· Novo Nordisk A/S· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity1 recruiting

Closed trials

• Withdrawn

  A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes

  NCT07357740· Phase 2· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

  NCT06534411· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

  NCT06221969· Phase 3· Novo Nordisk A/S· Source